CMXHF — CSL LTD
—
OTC ·
Unknown ·
Unknown ·
CIK 1274152 ·
Last close
$88.94
Market Cap
$42.59B
52W High
$91.75
52W Low
$63.84
ADV30
2,337
Next earnings
2026-08-17
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 8,213,000,000 | 4,279,000,000 | 1,977,000,000 | 2,007,000,000 | 38,447,000,000 | 1,524,000,000 | 17,901,000,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$17,331,000,000
Inventory
$6,139,000,000
Receivables
$3,606,000,000
ST Investments
—
EBIT TTM
$2,753,000,000
Pretax Income TTM
$2,540,000,000
Interest Exp TTM
$213,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,406,999,552
EBITDA
$4,840,000,000
Free Cash Flow
$1,848,125,056
Enterprise Value
$54,675,714,048
Total Cash
$1,144,999,936
Total Debt
$11,137,999,872
Shares Out
478,911,979
Trailing EPS
$6.17
Book Value
$38.70
ROE
6.7%
ROA
6.6%
Div Yield
3.25%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 15,430,000,000 | 2,959,000,000 | 3,002,000,000 | 39,404,000,000 | 17,997,000,000 | — | — |
| Jun 2024 | 14,690,000,000 | 2,764,000,000 | 2,642,000,000 | 38,022,000,000 | 18,621,000,000 | — | — |
| Jun 2023 | 13,174,000,000 | 2,102,000,000 | 2,194,000,000 | 36,234,000,000 | 18,408,000,000 | — | — |
| Jun 2022 | 10,493,100,000 | 2,316,100,000 | 2,254,700,000 | 28,346,000,000 | 13,768,500,000 | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DIA | SPDR DOW JONES INDUSTRIAL AVERAGE ETF TRUST | $42.60B | $524.32 | — |
| TRI | THOMSON REUTERS CORP /CAN/ | $42.84B | $98.13 | — |
| EBBNF | ENBRIDGE INC | $43.11B | $25.00 | — |
| PAYX | PAYCHEX INC | $41.56B | $116.84 | — |
| CSLLY | CSL LTD | $41.45B | $21.64 | — |
News headlines (Yahoo Finance, 1h cache)
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
2026-07-27 13:00 · Yahoo
Australia to challenge Trump’s new 12.5% tariff, says PM Albanese
2026-07-26 02:41 · Yahoo
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
2026-06-26 13:00 · Yahoo
Imugene strengthens board with biotech and pharma appointments
2026-05-26 00:56 · Yahoo
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada
2026-05-20 10:00 · Yahoo
3 ASX Dividend Stocks Yielding Up To 4.2%
2026-05-18 19:39 · Yahoo
CSL Plunges 22% After Cutting Outlook And Flagging $5 Billion Impairments
2026-05-11 12:38 · Yahoo
Should Value Investors Buy CSL Limited (CSLLY) Stock?
2026-05-04 13:40 · Yahoo
CSL Restructure And Seqirus Split Reset Expectations After Share Price Slide
2026-05-02 06:15 · Yahoo
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
2026-04-30 15:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.